검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Fludara |
Overview Company | Celyad Oncology SA |
Overview Modality | ANTIBODY |
Overview Target | FRα |
Overview Indication | Relapse/Refractory Multiple Myeloma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Biomarker | biomarker study in HLA-haploidentical hematopoietic cell transplant recipients |
PK/PD Half-life | 6 h |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis.. T cell receptor-engineered T cell (TCR-T) therapy has shown promising efficacy in advanced solid tumours. Lymphodepleting (LD) chemotherapy improves TCR-T cell therapy efficacy but is a… |
Clinical Primary efficacy | ORR 20.4% |
Clinical ORR | 20.4% |
Clinical OS | 10.3 |
Clinical Result source | ClinicalTrials.gov NCT03182244 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Fludara |
Overview Company | Celyad Oncology SA |
Overview Modality | ANTIBODY |
Overview Target | FRα |
Overview Indication | Relapse/Refractory Multiple Myeloma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Biomarker | biomarker study in HLA-haploidentical hematopoietic cell transplant recipients |
PK/PD Half-life | 6 h |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, In vitro |
Toxicology Major finding | Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis.. T cell receptor-engineered T cell (TCR-T) therapy has shown promising efficacy in advanced solid tumours. Lymphodepleting (LD) chemotherapy improves TCR-T cell therapy efficacy but is a… |
Clinical Primary efficacy | ORR 20.4% |
Clinical ORR | 20.4% |
Clinical OS | 10.3 |
Clinical Result source | ClinicalTrials.gov NCT03182244 |
Clinical Data Tier / Score | A · 41 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교